

Table 1. Clinicopathological features of the treated patients

Characteristics	Total sample (N=384)	Studied population (N=82)	Complementary (N=302)	p value
Age (yr)				
Median (min, max)	56 (28, 83)	55 (31, 82)	56 (28, 83)	0.363
Missing	0	0	0	
Age (yr)				
<=50, N(%)	120 (31.3)	29 (35.4)	91 (30.1)	0.365
>50, N(%)	264 (68.7)	53 (64.6)	211 (69.9)	
Missing	0	0	0	
Clinical T stage, N(%)				
T1	300 (78.1)	62 (75.6)	238 (78.8)	0.715
T2	75 (19.5)	19 (23.2)	56 (18.5)	
T3	6 (1.6)	1 (1.2)	5 (1.6)	
Missing	3 (0.8)	0	3 (1.1)	
Receptor Status, N(%)				
ER+ and/or PgR+	318 (82.8)	75 (91.5)	243 (82.1)	0.040
ER-/PgR-	60 (15.6)	7 (8.5)	53 (17.9)	
Missing	6 (1.6)	0	6	
HER2,N(%)				
HER2 +	59 (15.4)	10 (12.2)	49 (16.2)	0.408
HER2 -	182 (47.4)	40 (48.8)	142 (47)	
Missing	143 (37.2)	32 (39)	111 (36.8)	
LVI, N(%)				
Yes	34 (8,8)	13 (15.9)	21 (6.9)	0.012
No	349 (90.9)	69 (84.2)	280 (92.7)	
Missing	1 (0,3)	0	1 (0.4)	
Tumor type, N(%)				
Infiltrating ductal	317 (82,5)	66 (80.5)	251 (83.1)	0.314
Infiltrating lobular	13 (3.4)	5 (6.1)	8 (2.6)	
Other	48 (12.5)	10 (12.2)	38 (12.6)	
Missing	6 (1.6)	1 (1.2)	5 (1.7)	